Name: VERACYTE INC (VCYT) Stock
Brand: VERACYTE INC
Rating: 8 (3 reviews)

VCYT Latest News, Press Relases and Analysis

All

Press Releases

15 days ago - By: Chartmill

Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity

5 days ago - By: Zacks Investment Research - Mentions: PODD PAHC ITGR

ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates

14 days ago - By: Veracyte, Inc.

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

a month ago - By: Veracyte, Inc.

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

a month ago - By: Veracyte, Inc.

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

2 months ago - By: Veracyte, Inc.

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

2 months ago - By: Zacks Investment Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

2 months ago - By: Zacks Investment Research

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

2 months ago - By: Veracyte, Inc.

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

2 months ago - By: Veracyte, Inc.

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

2 months ago - By: Zacks Investment Research - Mentions: NEO TEM

Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership

2 months ago - By: Veracyte, Inc.

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

2 months ago - By: Zacks Investment Research

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

2 months ago - By: Zacks Investment Research

Here's Why Veracyte (VCYT) is a Strong Growth Stock

3 months ago - By: Zacks Investment Research - Mentions: CAH MEDP WGS

VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

3 months ago - By: The Motley Fool

Veracyte (VCYT) Q2 Revenue Jumps 14%

3 months ago - By: Zacks Investment Research - Mentions: SGHT

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

3 months ago - By: Veracyte, Inc.

Veracyte Announces Second Quarter 2025 Financial Results

3 months ago - By: Benzinga - Mentions: OEC VTLE DIN INSE ...

Earnings Scheduled For August 6, 2025

3 months ago - By: Yahoo Finance

Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion

3 months ago - By: Benzinga - Mentions: ADPT KTOS IRDM VEEV ...

Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics

3 months ago - By: Veracyte, Inc.

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

4 months ago - By: Veracyte, Inc.

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

4 months ago - By: Zacks Investment Research - Mentions: MYGN TEM

Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

5 months ago - By: Yahoo Finance - Mentions: TSLA PLTR ARKK AMD ...

Cathie Wood sells $22.8 million of hot stock near all-time highs

5 months ago - By: Yahoo Finance - Mentions: ENB IART NEM DOW ...

Enbridge Is One of the Largest Energy Companies by Market Cap. But Is It a Buy?

5 months ago - By: Zacks Investment Research - Mentions: IART

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

5 months ago - By: Yahoo Finance - Mentions: REGN TBIO SCYX PEPG ...

Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency

5 months ago - By: Veracyte, Inc.

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

5 months ago - By: Veracyte, Inc.

VERACYTE INC (VCYT) Stock News

VCYT Latest News, Press Relases and Analysis

Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity

ITGR Shares Down Despite Q3 Earnings & Revenues Beat Estimates

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today

Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Tempus' Key Acquisitions Strengthen Its AI Healthcare Leadership

Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test

Here's Why Veracyte (VCYT) is a Strong Momentum Stock

Here's Why Veracyte (VCYT) is a Strong Growth Stock

VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up

Veracyte (VCYT) Q2 Revenue Jumps 14%

Veracyte (VCYT) Tops Q2 Earnings and Revenue Estimates

Veracyte Announces Second Quarter 2025 Financial Results

Earnings Scheduled For August 6, 2025

Veracyte (VCYT) Soars 7% on S&P SmallCap 600 Inclusion

Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

Cathie Wood sells $22.8 million of hot stock near all-time highs

Enbridge Is One of the Largest Energy Companies by Market Cap. But Is It a Buy?

Veracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?

Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

Veracyte to Participate in Upcoming Investor Conferences